CanSino Biologics Inc.
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 2009-01-13
- Employees
- 1.4K
- Market Cap
- -
- Website
- http://www.cansinotech.com
- Introduction
The company was founded in 2009 in China. It is an industry-leading high-tech biological products company with the mission of providing solutions for the prevention and treatment of infectious diseases worldwide, focusing on the R&D, production and commercialization of innovative, high-quality, and accessible human vaccines. Cansino Biotech's mission has always been to “provide the world with innovative, high-quality, and accessible vaccines” to achieve the corporate vision of “endless innovation, a world free of diseases”. The company is an innovative vaccine enterprise dedicated to the development, production and commercialization of innovative vaccines that meet Chinese and international standards. The marketed products and product pipeline cover the prevention of meningitis, pneumonia, tuberculosis, COVID-19, Ebola virus disease, shingles, tuberculosis, and many other vaccine varieties with high clinical demand. The main products are MCV4, MCV2, AD5-nCoV, inhaled AD5-nCoV and xBB.1.5 variant vaccines, AD5-eBoV, etc. Corporate honors: National High-tech Enterprise, Tianjin Key Laboratory for Respiratory Bacterial Recombination and Combined Vaccine Enterprises, Nankai University Talent Training Cooperation and Development Base, Tianjin Model Group, etc.
Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults
- Conditions
- COVID-19
- Interventions
- Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- CanSino Biologics Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT04313127
- Locations
- 🇨🇳
Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China
Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above
- Conditions
- Streptococcal InfectionsBacterial InfectionsPneumococcal Infections
- Interventions
- Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- CanSino Biologics Inc.
- Target Recruit Count
- 237
- Registration Number
- NCT04100772
- Locations
- 🇨🇳
Neihuang Center for Disease Control and Prevention, Anyang, Henan, China
Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .
- Conditions
- DiphtheriaTetanusPertussis
- Interventions
- Biological: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, AdsorbedBiological: Diphtheria-tetanus-acellular pertussis vaccineBiological: Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccineBiological: Diphtheria and Tetanus Combined Vaccine, Adsorbed
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- CanSino Biologics Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT04099303
- Locations
- 🇨🇳
Changge Center for Disease Control and Prevention, Xuchang, Henan, China
Phase Ⅰa Clinical Trial of a Pneumococcal Vaccine
- Conditions
- Respiratory Tract DiseasesRespiratory Tract InfectionsPneumonia
- Interventions
- Biological: Protein based pneumococcal vaccine placebo(Middle dose)Biological: Protein based pneumococcal vaccine(Low dose)Biological: Protein based pneumococcal vaccine placebo(Low dose)Biological: Protein based pneumococcal vaccine(Middle dose)Biological: Protein based pneumococcal vaccine placebo(High dose)Biological: Protein based pneumococcal vaccine(High dose)
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- CanSino Biologics Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT04087460
- Locations
- 🇨🇳
Suixian Center for Disease Control and Prevention, Shangqiu, Henan, China